Single dose pharmacokinetic study of HP-3060
Phase 2
Completed
- Conditions
- Allergic rhinitis
- Registration Number
- JPRN-jRCT2080223788
- Lead Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Patients who a diagnosis of allergic rhinitis and symptoms of this condition.
Exclusion Criteria
- Patients who have a history of hypersensitivity to any medicines.
- Patients who may be affected by blood sampling in the study following blood collection or bleeding within 4 weeks prior to study drug administration.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method